3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
3
Support of the Family as a Caregiving System
1
Stomach Neoplasms
1
Otorhinolaryngologic Neoplasms
1
Mixed Dementias
1
Meningeal Carcinomatosis
1
Malignant Female Reproductive System Neoplasm
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Localized Head and Neck Carcinoma
1
Lewy Body Disease
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Dementia, Vascular
1
Dementia
1
Cognitive Dysfunction
1
Cigarette Smoking-Related Carcinoma
1
Anxiety Disorders
1
Interventions
lutetium Lu 177 dotatate
12
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
pembrolizumab
5
cabozantinib
5
Everolimus
5
Nivolumab
4
olaparib
3
lenvatinib
3
Cyclophosphamide
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
lanreotide
2
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Radiotherapy
2
Phantoms, Imaging
2
Octreotide
2
Lutetium-177
2
Ipilimumab
2
Etoposide
2
Cisplatin
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
telotristat ethyl
1
surufatinib
1
repotrectinib
1
peposertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Referral and Consultation
×
90 days
×
Clear all
No trials found.